BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 35350909)

  • 1. Real-world management of targeted therapies in chronic lymphocytic leukemia.
    Weis TM; Gutierrez J; Kabel CC; King AC; Daley RJ; Stump SE
    J Oncol Pharm Pract; 2022 Sep; 28(6):1411-1433. PubMed ID: 35350909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies.
    Rainone M; Siddiqi T
    Curr Hematol Malig Rep; 2022 Feb; 17(1):39-45. PubMed ID: 35028825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BTK Inhibitors in Chronic Lymphocytic Leukemia.
    Gaballa S; Pinilla-Ibarz J
    Curr Hematol Malig Rep; 2021 Oct; 16(5):422-432. PubMed ID: 34599723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections.
    Hilal T; Gea-Banacloche JC; Leis JF
    Blood Rev; 2018 Sep; 32(5):387-399. PubMed ID: 29571669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia.
    Marini BL; Samanas L; Perissinotti AJ
    J Oncol Pharm Pract; 2017 Oct; 23(7):502-517. PubMed ID: 27357816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy combinations for chronic lymphocytic leukemia: advantages and disadvantages.
    Robak P; Robak T
    Expert Opin Biol Ther; 2023 Jan; 23(1):21-35. PubMed ID: 36374125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibrutinib combinations in CLL therapy: scientific rationale and clinical results.
    Timofeeva N; Gandhi V
    Blood Cancer J; 2021 Apr; 11(4):79. PubMed ID: 33927183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.
    Hallek M; Al-Sawaf O
    Am J Hematol; 2021 Dec; 96(12):1679-1705. PubMed ID: 34625994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment strategies for chronic lymphocytic leukemia in the era of novel targeted therapies].
    Kojima K
    Rinsho Ketsueki; 2020; 61(9):1275-1280. PubMed ID: 33162526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.
    Small S; Ma S
    Curr Hematol Malig Rep; 2021 Aug; 16(4):325-335. PubMed ID: 34021874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia.
    Miao Y; Xu W; Li J
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1023-1030. PubMed ID: 34275396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy.
    Roeker LE; Thompson M; Mato AR
    Drugs; 2022 Feb; 82(2):133-143. PubMed ID: 34932207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
    Jain N; O'Brien S
    Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia.
    Bennett R; Anderson MA; Seymour JF
    J Hematol Oncol; 2023 Jul; 16(1):72. PubMed ID: 37422670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic Lymphocytic Leukemia (CLL): Biology and Therapy.
    Siddiqi T
    Cancer Treat Res; 2021; 181():133-149. PubMed ID: 34626359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm.
    Scheffold A; Stilgenbauer S
    Curr Oncol Rep; 2020 Feb; 22(2):16. PubMed ID: 32025827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
    Thompson PA; Burger JA
    Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic lymphocytic leukemia therapy: new targeted therapies on the way.
    Vitale C; Burger JA
    Expert Opin Pharmacother; 2016 Jun; 17(8):1077-89. PubMed ID: 26988407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
    Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
    Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.